TABLE 5.
Risk Factors for Incident Complications in 53 Eyes with HLA-B27-associated Uveitis
| Predictors | Crude Hazard Ratio (95% CI, P)a | Adjusted Hazard Ratio (95% CI, P)b |
|---|---|---|
| Duration of uveitis prior to presentation (years) | 1.0 (0.97–1.0, 0.62) | |
| Male | 0.91 (0.42–2.0, 0.80) | |
| Caucasian vs other | 1.0 (0.45–2.4, 0.93) | |
| Chronic disease | 2.8 (1.3–5.0, 0.006) | 2.2 (1.0–4.6, 0.04) |
| HLA-B27 systemic disease | 1.1 (0.51–2.5, 0.76) | |
| Inflammationc | 0.88 (0.30–2.6, 0.82) | |
| Corticosteroid-sparing therapyc | 1.3 (0.56–2.9, 0.56) | |
| Oral corticosteroidsc | 1.0 (0.27–3.8, 0.97) | |
| Topical corticosteroidsc | 3.2 (1.4–7.4, 0.007) | 3.3 (1.3–8.4, 0.01) |
| Corticosteroid injectionsc | 3.0 (1.6–16, 0.005) |
a
Crude HR = hazard ratio (95% CI = 95% confidence interval, P value) for univariate Cox proportional hazard model using robust feature.
b
Adjusted HR = hazard ratio (95% CI = 95% confidence interval, P value) for multivariate analyses in which all exposure variables were included and stepwise regression utilized to eliminate all variables with P values ≥0.30.
c
Time-updated variables